All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Follow-up data obtained from the TRANSCEND NHL 001 trial (NCT02631044) demonstrates that treatment with lisocabtagene maraleucel (liso-cel) leads to long-lasting responses in patients with relapsed/refractory large B-cell lymphoma. Below, we summarize the data as presented at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR[MM1] .1
Liso-cel is an autologous, CD19-directed, defined composition, 4-1BB chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8+ and CD4+ T cells. The therapy was recently approved by the European Commission as a ≥third-line treatment for certain forms of relapsed or refractory large B-cell lymphoma.
At the 2-year follow-up, the TRANSCEND NHL 001 study met all of its primary and secondary endpoints.
Of the 269 patients who received liso-cel, 257 were evaluable for efficacy:
In conclusion, liso-cel demonstrated durable remission rates and a promising safety profile in the 2-year follow-up of TRANSCEND NHL 001. Treatment was associated with a low incidence of severe cytokine release syndrome and neurological events. There were no additional safety concerns observed in this follow-up, and most of the adverse events occurred in the treatment-emergent reporting period.
Liso-cel treatment in the outpatient setting
During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, Carlos Bachier presented the results of a study evaluating the safety and efficacy of liso-cel in patients with R/R LBCL who...
Correlation of patient type and inflammation biomarkers with clinical outcomes in JCAR017 treatment – ASH 2017 Oral Abstract #193
Low tumor burden and low inflammatory state are associated with improved toxicity profile and a more durable response.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox